{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Ftrk-inhibitors-faq-fKzldww7","width":444,"version":"1.0","type":"rich","title":"Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/48df81f0-2498-4cb9-8f7b-dcdacec1059d/cliniciansxchange-podcast-ntrk.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/15592832-5e0d-407c-a702-faf736bf5e45\" height=\"200\" width=\"100%\" title=\"Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer audience questions from a series of live CCO Webinars focused on when and how to test for NTRK fusions in solid tumors and best practices in using TRK inhibitors. "}